CuraGen to Present CR011-vcMMAE Data at ASCO
28 May 2009 - 8:30PM
PR Newswire (US)
- Update from Advanced Breast Cancer and Melanoma Studies BRANFORD,
Conn., May 28 /PRNewswire-FirstCall/ -- CuraGen Corporation
(NASDAQ:CRGN) today announced plans for three data presentations
from its ongoing clinical trials of CR011-vcMMAE, an antibody-drug
conjugate that targets GPNMB, in patients with advanced breast
cancer and melanoma at the 2009 Annual Meeting of the American
Society of Clinical Oncology (ASCO) in Orlando, Florida. The
titles, dates, and times of the presentations are as follows: #9032
A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate
targeting glycoprotein NMB in patients with advanced melanoma.
Sunday, May 31, 2009, poster presentation from 8:00 AM - 12:00 PM
with a discussion session from 11:30 AM - 12:30 PM. #9063
Pharmacokinetics of CR011-vcMMAE, an antibody-drug conjugate, in a
phase I study of patients with advanced melanoma. Monday, June 1,
2009, poster presentation from 8:00 AM - 12:00 PM. #1067 A phase
I/II study of CR011-vcMMAE, an antibody-drug conjugate, in patients
with locally advanced or metastatic breast cancer. Monday, June 1,
2009, poster presentation from 1:00 PM - 5:00 PM. Abstracts are
available and can be viewed on the ASCO Web site at
http://www.asco.org/. Reprints of the presentations will be made
available on CuraGen's website at http://www.curagen.com/ or can be
requested by emailing following the presentations. Conference Call
Details and Dial-in Information Date: Wednesday, June 3, 2009 Time:
11:00 a.m. EDT Dial-in: (877)-856-1956 (U.S. and Canada)
(719)-325-4771 (international) Webcast: Access available at
http://www.curagen.com/ About CR011-vcMMAE CR011-vcMMAE is an
antibody-drug conjugate (ADC) being developed by CuraGen that
consists of a fully-human monoclonal antibody, CR011, linked to a
potent cell-killing drug, monomethyl-auristatin E (MMAE). The ADC
technology, comprised of MMAE and a stable linker system for
attaching it to CR011, was licensed from Seattle Genetics, Inc. The
ADC is designed to be stable in the bloodstream. Following
intravenous administration, CR011-vcMMAE targets and binds to
GPNMB, a specific protein that is predominantly expressed on the
surface of cancer cells, including melanoma, breast cancer and
gliomas. Upon internalization into the targeted cell, CR011-vcMMAE
is designed to release MMAE from CR011 to produce a cell-killing
effect. CR011-vcMMAE is currently in two Phase II trials assessing
the safety and efficacy in the treatment of melanoma and for the
treatment of metastatic breast cancer, and in a Phase I trial to
evaluate the safety and activity of alternate dosing schedules.
About Breast Cancer Breast cancer is the most common cancer in
women and a leading cause of death in the United States. According
to the American Cancer Society, more than 180,000 women will be
diagnosed with invasive breast cancer in 2009 with more than 40,000
deaths attributed to this disease. Despite recent advances in
therapy, the median survival of patients with metastatic breast
cancer is 2 to 3 years, while patients with "triple-negative" or
"basal-like" breast cancer have limited treatment options and
poorer outcomes. Therefore, a significant unmet need remains for
novel therapeutic approaches for patients with locally advanced and
metastatic breast cancer who have failed other therapies. About
Melanoma According to the American Cancer Society, it is expected
that approximately 60,000 new cases of melanoma will be diagnosed,
including nearly 11,000 patients diagnosed with Stage III or Stage
IV disease, and an estimated 8,000 people in the U.S. will die of
the disease during 2009. The prognosis for patients with advanced
melanoma is poor, and studies have shown that the median survival
is less than nine months. About CuraGen CuraGen Corporation
(NASDAQ:CRGN) is a clinical-stage biopharmaceutical company
developing promising approaches for the treatment of cancer.
CuraGen Corporation is headquartered in Branford, Connecticut. For
additional information please visit http://www.curagen.com/.
Forward-Looking Statements Statements in this press release
regarding management's future expectations, beliefs, intentions,
goals, strategies, plans or prospects, including statements
relating to CuraGen's development program for CR011-vcMMAE,
including CuraGen's ability to advance CR011-vcMMAE through Phase
II clinical trials for melanoma and metastatic breast cancer, to
explore additional doses and schedules of this antibody-drug
conjugate, and to explore the potential of CR011-vcMMAE in a
patient population in need of new therapies may constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by terminology such as "anticipate,"
"believe," "could," "could increase the likelihood," "estimate,"
"expect," "intend," "is planned," "may," "should," "will," "will
enable," "would be expected," "look forward," "may provide,"
"would" or similar terms, variations of such terms or the negative
of those terms. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors including the risk
that any one or more of CuraGen's drug development programs will
not proceed as planned for technical, scientific or commercial
reasons or due to patient enrollment issues or based on new
information from nonclinical or clinical studies or from other
sources, the success of competing products and technologies,
CuraGen's stage of development as a biopharmaceutical company,
government regulation and healthcare reform, technological
uncertainty and product development risks, product liability
exposure, uncertainty of additional funding, CuraGen's history of
incurring losses and the uncertainty of achieving profitability,
reliance on research collaborations and strategic alliances,
competition, patent infringement claims against CuraGen's products,
processes and technologies, CuraGen's ability to protect its
patents and proprietary rights and uncertainties relating to
commercialization rights, as well as those risks, uncertainties and
factors referred to in CuraGen's Quarterly Report on Form 10-Q for
the period ended March 31, 2009 filed with the Securities and
Exchange Commission under the section "Risk Factors," as well as
other documents that may be filed by CuraGen from time to time with
the Securities and Exchange Commission. As a result of such risks,
uncertainties and factors, CuraGen's actual results may differ
materially from any future results, performance or achievements
discussed in or implied by the forward-looking statements contained
herein. CuraGen is providing the information in this press release
as of this date and assumes no obligations to update the
information included in this press release or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise. CRGN-P Contacts: Sean Cassidy Chief
Financial Officer Ronit Simantov Chief Medical Officer (888)-
436-6642 DATASOURCE: CuraGen Corporation CONTACT: Sean Cassidy,
Chief Financial Officer, , or Ronit Simantov, Chief Medical
Officer, , both of CuraGen, +1-888-436-6642 Web Site:
http://www.curagen.com/
Copyright
Curagen Corp. (MM) (NASDAQ:CRGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Curagen Corp. (MM) (NASDAQ:CRGN)
Historical Stock Chart
From Jul 2023 to Jul 2024